Intravenous drip infusing iron, symbolizing restoration and healing.

Iron Infusion for Anemia: Is Ferric Carboxymaltose the Right Choice?

Author's portrait.
Samir D’Costa in Health & Wellness December 2025 • 5 min read.

"A comprehensive look at using ferric carboxymaltose (FC) for preoperative anemia management to reduce blood transfusions, including effectiveness, safety, and patient selection."


Anemia, a condition characterized by a deficiency of red blood cells or hemoglobin in the blood, poses a significant challenge in patients undergoing surgery. Preoperative anemia increases the risk of complications, including increased blood transfusions, longer hospital stays, and even mortality. Therefore, effective management of preoperative anemia is crucial for improving patient outcomes.

Traditionally, blood transfusions have been the primary approach to correct preoperative anemia. However, transfusions carry risks such as infections, allergic reactions, and transfusion-related acute lung injury (TRALI). Moreover, blood supplies are often limited, making transfusions a less than ideal solution. As a result, alternative strategies for managing preoperative anemia have gained increasing attention.

One such strategy is the use of intravenous (IV) iron, particularly ferric carboxymaltose (FC). FC is a rapidly administered, high-dose IV iron formulation that has shown promise in effectively raising hemoglobin levels and reducing the need for blood transfusions in patients undergoing surgery. This article will delve into the use of FC for preoperative anemia management, exploring its effectiveness, safety, and appropriate patient selection based on recent research.

Ferric Carboxymaltose: A Fast Track to Higher Hemoglobin

Intravenous drip infusing iron, symbolizing restoration and healing.

A study conducted at the Hospital Universitario Fundación Jimenez Diaz investigated the use of ferric carboxymaltose (FC) within a system designed for preoperative hemoglobin (Hb) optimization. The goal was to reduce blood transfusions in patients with anemia scheduled for surgery. The study retrospectively analyzed data from patients who received at least one dose of FC in 2011, evaluating adherence to the hospital's Hb optimization protocol and the effectiveness of the treatment.

The study included 47 patients with a wide age range (23 to 87 years), and the results indicated that FC was indeed effective in raising hemoglobin levels quickly. Specifically, patients receiving a single administration of 500 mg of FC experienced an average increase of 0.6 g/dL in Hb, while those receiving 1000 mg saw an increase of 1 g/dL. Patients who had previously received other forms of IV iron saw an even more significant increase, with a median of 2.05 g/dL after FC administration (total average dose of iron administered: 1150 mg).

  • Rapid Hemoglobin Increase: FC effectively and quickly raises hemoglobin levels before surgery.
  • Reduced Transfusion Needs: By optimizing Hb levels, FC helps minimize the need for blood transfusions, reducing associated risks and resource demands.
  • Protocol Adherence: The study highlights the importance of following established protocols for anemia management to achieve the best outcomes.
These findings suggest that FC can be a valuable tool for preoperative anemia management, particularly when a rapid increase in hemoglobin is needed. However, the study also emphasizes the importance of patient selection and protocol adherence to ensure optimal results.

The Future of Anemia Management: FC and Beyond

The study from Hospital Universitario Fundación Jimenez Diaz provides compelling evidence for the effectiveness of ferric carboxymaltose in preoperative anemia management. However, it's important to consider all aspects of its use. The decision to use FC should be based on a comprehensive evaluation of the patient's condition, including the severity of anemia, the urgency of surgery, and any underlying medical conditions.

While FC offers a rapid and effective means of raising hemoglobin levels, it is not without potential risks. As with any IV iron formulation, there is a risk of hypersensitivity reactions. Common side effects include nausea, headache, and dizziness. More serious, though rare, side effects include anaphylaxis and iron overload. Healthcare providers should carefully monitor patients receiving FC and be prepared to manage any adverse reactions.

Moving forward, further research is needed to refine patient selection criteria for FC therapy and to optimize treatment protocols. Additionally, studies are needed to compare the long-term outcomes of patients managed with FC to those managed with other strategies, such as blood transfusions or oral iron supplementation. With continued research and careful clinical application, FC has the potential to significantly improve the outcomes of patients undergoing surgery.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

1

What exactly is ferric carboxymaltose, and how does it help with anemia?

Ferric carboxymaltose, or FC, is a specific formulation of intravenous iron used to rapidly increase hemoglobin levels in patients with anemia, particularly before surgery. It's favored for its ability to deliver high doses of iron quickly, helping to reduce or eliminate the need for blood transfusions. The effectiveness of FC has been demonstrated in clinical settings, showing significant improvements in hemoglobin levels following its administration.

2

Why is ferric carboxymaltose considered a better option than traditional blood transfusions for preoperative anemia?

Traditionally, blood transfusions have been the primary method for correcting preoperative anemia. However, blood transfusions have associated risks such as infections, allergic reactions, and transfusion-related acute lung injury, or TRALI. Additionally, the availability of blood supplies can be limited. Ferric carboxymaltose provides an alternative by directly addressing iron deficiency, the root cause of many anemia cases, thus reducing reliance on transfusions and their inherent risks.

3

How quickly does ferric carboxymaltose raise hemoglobin levels before surgery, according to research?

According to a study at the Hospital Universitario Fundación Jimenez Diaz, patients who received ferric carboxymaltose experienced a rapid increase in hemoglobin levels. A single 500 mg dose of FC resulted in an average increase of 0.6 g/dL, while a 1000 mg dose led to an increase of 1 g/dL. Patients previously treated with other IV iron formulations saw a median increase of 2.05 g/dL after FC administration. This indicates that FC is effective for quickly raising hemoglobin levels before surgery.

4

Is ferric carboxymaltose suitable for all patients with preoperative anemia, and what factors determine its appropriate use?

While ferric carboxymaltose is effective for many, patient selection is crucial. The decision to use FC should be based on a comprehensive evaluation of the patient's condition, considering the severity of anemia, the urgency of the surgery, and any underlying medical conditions. Following established protocols for anemia management is essential to ensure optimal results. However, the text lacks discussion of specific contraindications or conditions where FC might not be appropriate, such as certain kidney conditions or iron overload disorders, which would typically be part of patient selection considerations.

5

In what ways does using ferric carboxymaltose to treat anemia before surgery contribute to reducing the need for blood transfusions?

Ferric carboxymaltose helps reduce the need for blood transfusions by directly addressing the iron deficiency that causes anemia. By raising hemoglobin levels quickly, FC minimizes the need for transfusions, which carry risks like infections, allergic reactions, and TRALI. Reducing blood transfusions not only improves patient safety but also alleviates the demand on blood supplies and reduces healthcare costs associated with transfusion-related complications. This approach aligns with patient blood management strategies, prioritizing the use of the patient's own blood and minimizing exposure to donor blood.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.